SCHEMBL23879233

SCHEMBL23879233

CNC(=O)c1ccc(Cl)c(C(C(N)=O)c2ccc(Cl)nn2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 1/20 0.37
LMNA P02545 2/20 0.35
KMT2A Q03164 1/20 0.35
THRB P10828 1/20 0.35
KCNH2 Q12809 1/20 0.35
HTT P42858 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
MAPT P10636 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
PYGL P06737 1/20 0.34
ESR2 Q92731 2/20 0.34
KDM4E B2RXH2 1/20 0.34
KCNQ3 O43525 1/20 0.34
KCNQ2 O43526 1/20 0.34
KCNE1 P15382 1/20 0.34
KCNQ1 P51787 1/20 0.34
HPGD P15428 1/20 0.33
BCAT2 O15382 1/20 0.33
S1PR3 Q99500 1/20 0.33
SLC6A2 P23975 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30452681 1.00 PLAU (0.37) PLAULMNAKMT2ATHRBKCNH2
SCHEMBL23879240 0.85 TSHR (0.41) LMNAKMT2ATHRBKCNH2HTT
SCHEMBL30452623 0.85 TSHR (0.41) LMNAKMT2ATHRBKCNH2HTT
SCHEMBL30452602 0.81 HTT (0.45) LMNAKMT2AKCNH2HTTSMN1; SMN2
SCHEMBL23879258 0.81 HTT (0.45) LMNAKMT2AKCNH2HTTSMN1; SMN2
SCHEMBL24252035 0.74 HPGD (0.47) PLAULMNAKMT2AKCNH2HTT
SCHEMBL30452460 0.74 MAPT (0.44) LMNAKMT2AHTTSMN1; SMN2MAPT
SCHEMBL23879245 0.74 MAPT (0.44) LMNAKMT2AHTTSMN1; SMN2MAPT
SCHEMBL30452606 0.74 MAPT (0.44) LMNAKMT2AHTTSMN1; SMN2MAPT
SCHEMBL23879241 0.73 ALDH1A1 (0.55) LMNAKMT2AHTTSMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111253404-B Nitrogen-containing heterocyclic compound and composition, preparation method and application thereof 上海医药集团股份有限公司 2023-05-23 CN disclosed
US-20220048915-A1 Nitrogen-containing Heterocyclic Compound and Composition Thereof, Preparation Method Therefor, and Application Thereof SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2022-02-17 US disclosed
EP-3889156-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Shanghai Pharmaceuticals Holding Co., Ltd. (CN) 2021-10-06 EP disclosed
CN-111253404-A Nitrogen-containing heterocyclic compound and composition, preparation method and application thereof 上海医药集团股份有限公司 2020-06-09 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048915-A1 Nitrogen-containing Heterocyclic Compound and Composition Thereof, Preparation Method Therefor, and Application Thereof MAPK11, WEE1, NOS1 PLAU 4141/4885LMNA 2598/4885KMT2A 3961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.